Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Artivion鈥檚 FDA updates, clinical-trial costs, and global device revenues can feel overwhelming when each SEC report stretches well past 200 pages. Whether you are tracking new aortic stent graft approvals or trying to spot shifts in mechanical heart-valve demand, the technical language in an Artivion annual report 10-K or a fresh 10-Q quarterly earnings report often masks the insights that drive decisions.
Stock Titan solves this problem. Our AI engine turns every filing into plain-English takeaways鈥�Artivion SEC filings explained simply. Get instant alerts the moment an Artivion 8-K material event lands on EDGAR, skim AI-generated risk highlights, or drill straight into segment revenue tables without sifting through footnotes. Need to monitor management鈥檚 sentiment? AG真人官方-time dashboards surface Artivion Form 4 insider transactions so you can gauge executive conviction ahead of pivotal FDA milestones.
The platform covers every document type investors ask about:
- 10-K sections on product liability and clinical data鈥攁lready summarized and compared year-over-year.
- 10-Q snapshots for revenue growth by valve, graft, and adhesive lines鈥攊deal for quick Artivion earnings report filing analysis.
- 8-K event briefs that explain recall notices or trial results in minutes.
- Proxy statements outlining Artivion executive compensation and option grants.
- Form 4 dashboards showing Artivion insider trading Form 4 transactions in real time.
Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc. (AORT), exercised stock options and sold an equal number of shares on 08/27/2025. He exercised a stock option with an $11.03 exercise price to acquire 18,200 shares and simultaneously sold 18,200 shares at a weighted average price of $44.023 per share. Following these transactions, Mr. Stanton beneficially owned 64,200 shares of Artivion common stock.
The option exercised had an original grant with a first exercisable date of 11/08/2023 and a stated vesting schedule of 33 1/3% per year. The filing notes the sale price range was $43.84 to $44.26 and that the reporting person can provide a breakdown of shares sold at each price upon request.
Artivion, Inc. (AORT) Form 144 discloses a proposed sale of 18,200 common shares through Morgan Stanley Smith Barney with an aggregate market value of $801,211.32. The shares were acquired and are listed for sale with an approximate sale date of 08/27/2025 following a stock option exercise paid in cash on the same date. The filing shows total shares outstanding of 47,183,658 and lists two prior sales by the same person in June 2025 of 15,000 and 26,132 shares, with gross proceeds of $442,500.00 and $743,129.66 respectively.
Jean F. Holloway, SVP & General Counsel of Artivion, Inc. (AORT), reported transactions on 08/25/2025. She exercised a stock option to acquire 10,000 shares at an exercise price of $11.03 per share and concurrently sold 10,000 shares at $44.37 per share. After these transactions she beneficially owned 172,129 shares. The option exercised relates to a grant with an $11.03 exercise price, originally exercisable beginning 11/08/2023 and expiring 11/08/2029; the option vests 33 1/3% per year starting on the first anniversary of the grant date.
Artivion, Inc. (AORT) Form 144 notice reports proposed sale of 10,000 common shares by an insider via Morgan Stanley Smith Barney LLC, with an aggregate market value of $443,700 and an approximate sale date of 08/25/2025. The form shows those shares were acquired and paid for on 08/25/2025 through a stock option exercise with cash payment. The filing also discloses two recent common-stock sales by JEAN F HOLLOWAY: 23,356 shares sold on 08/12/2025 for $1,004,605.97 and 8,748 shares sold on 05/27/2025 for $253,692.00. The filer affirms no undisclosed material adverse information.
James P. Mackin, President & CEO and director of Artivion, Inc. (AORT), reported a sale of common stock on 08/15/2025. The Form 4 shows he sold 12,500 shares at a weighted average price of $42.319 (prices ranged $42.25 to $42.585). After the transaction he beneficially owned 852,783 shares. The filing is signed 08/19/2025 and the reporting person notes availability of per-price sale details upon request.
Form 144 notice for Artivion, Inc. (AORT) shows a proposed sale of 12,500 common sharesRBC Capital Markets with an aggregate market value of $528,991. The filing lists the approximate sale date as 08/15/2025 and the shares outstanding as 47,183,658. The shares were acquired in open-market purchases: 5,000 shares on 11/13/2019 and 7,500 shares on 11/13/2019 (with payment dated 09/16/2020 for the second lot). The filer reports no sales in the past three months and makes the standard representation about material undisclosed information.
Jean F. Holloway, SVP and General Counsel of Artivion, Inc. (AORT), reported securities transactions dated 08/12/2025. She exercised stock options covering 16,975 underlying shares with a conversion/exercise price of $26.24 (option grant dated 02/19/2021, vesting 33 1/3% per year and first exercisable on 02/19/2021). On the same date she sold 16,975 shares at a weighted-average price of about $43.011 and an additional 6,381 shares at about $43.018. The filings show her beneficial ownership moved from 195,485 shares to 178,510 and then to 172,129 shares following the reported transactions. Footnotes disclose the weighted-average sale price ranges and offer to provide per-price details on request.
John E. Davis, Chief Commercial Officer of Artivion, Inc. (AORT), exercised 10,802 stock options with an exercise price of $26.24 per share and acquired 10,802 common shares on 08/12/2025. He then sold the same 10,802 shares at a weighted-average price of $43.673, with reported sale prices ranging $43.470鈥�$43.835.
Following these transactions Mr. Davis beneficially owns 208,778 shares. The exercised options were from a grant dated 02/19/2021 that vests 33 1/3% per year and expires 02/19/2027. The filing notes detailed per-price sale information is available upon request.
Artivion, Inc. (AORT) filed a Form 144 reporting a proposed sale of common stock. The filing shows 10,802 shares intended for sale on 08/12/2025 through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $471,752.51. The issuer's outstanding shares are listed as 47,183,658.
The securities were acquired on 08/12/2025 through a stock option exercise from the issuer and paid in cash. The filer reports "Nothing to Report" for securities sold during the past three months. The notice includes the standard representation that the seller does not possess undisclosed material adverse information about the issuer.
Artivion, Inc. (AORT) has a Form 144 notice reporting a proposed sale of 23,356 common shares with an aggregate market value of $1,004,605.97. The sale is listed as occurring approximately on 08/12/2025 on the NYSE through Morgan Stanley Smith Barney LLC.
The filing shows how the shares were acquired: 6,381 as restricted stock on 02/19/2019 and 16,975 via a stock option exercise on 08/12/2025 paid in cash. The form also discloses multiple insider sales in May 2025 by JEAN F HOLLOWAY, including transactions on 05/21/2025 and 05/27/2025, each with listed share amounts and gross proceeds. The filer affirms no undisclosed material adverse information.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
